PLx Pharma Inc (NASDAQ:PLXP) shares rose Tuesday trading after the company said its VAZALORE will launch in over 8,000 Walgreens stores nationwide in August.
VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.
Said CEO Natasha Giordano, "As we continue to execute on our commercial launch plans, we are delighted that Walgreens has committed to carrying all three SKUs of VAZALORE in over 8,000 of its stores throughout the country. Walgreens’ focus on health and wellbeing aligns closely with our mission to bring VAZALORE to the millions of people who can benefit from our unique aspirin therapy."
PLx is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.
PLXP shares hiked $2.62, or 15.4%, to $19.60.
